Literature DB >> 6372452

Factors predicting development of renal involvement in progressive systemic sclerosis.

V D Steen, T A Medsger, T A Osial, G L Ziegler, A P Shapiro, G P Rodnan.   

Abstract

Renal involvement or "scleroderma renal crisis" developed in 60 patients with progressive systemic sclerosis evaluated at the University of Pittsburgh during the period from 1972 to 1982. Forty-seven of these patients had progressive systemic sclerosis with diffuse scleroderma, representing 18 percent of persons with progressive systemic sclerosis and diffuse scleroderma evaluated during this time period. Ten additional patients did not have truncal scleroderma but were suspected of having incompletely developed diffuse scleroderma. Only three patients were classified as having progressive systemic sclerosis with the CREST syndrome. Renal crisis was observed early in the course of the illness, a mean of 3.2 years after onset. During May and June, this complication developed in fewer patients than expected. Thirty-six patients who had diffuse scleroderma and renal involvement after their initial Pittsburgh evaluation were compared with 212 who had diffuse scleroderma without renal involvement during follow-up. The patients with renal involvement had a shorter mean disease duration at the time of their first evaluation (2.4 versus 4.2 years, p less than 0.05) and less frequently had digital pitting scars (29 versus 54 percent), but no other significant clinical, laboratory, or serologic differences were noted. Data available for 31 patients with renal involvement during the six months preceding the onset of renal disease were analyzed. Blood pressure, serum creatinine, urine protein and red blood cells, and plasma renin levels were similar in these patients and the 212 patients without renal involvement. More patients with renal involvement had anemia or clinical evidence of cardiac involvement during this period compared with the patients without renal involvement. During the 12-month period prior to renal involvement, seven of 16 (44 percent) patients with such involvement had an impressive increase in skin thickening on physical examination compared with only 23 of 180 (14 percent) patients without renal involvement at any time during their course. Thus, the subset of patients with diffuse scleroderma who show rapid progression of their skin thickening early in the illness with development of anemia, pericardial effusion, or congestive heart failure have a high risk of "scleroderma renal crisis."

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6372452     DOI: 10.1016/0002-9343(84)90986-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  35 in total

Review 1.  Scleroderma renal crisis: new insights and developments.

Authors:  Elisa Y Rhew; Walter G Barr
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

2.  Renal disease in systemic sclerosis with normal serum creatinine.

Authors:  Reem H A Mohamed; Hania S Zayed; Amr Amin
Journal:  Clin Rheumatol       Date:  2010-02-23       Impact factor: 2.980

3.  HLA-DRB1*0407 and *1304 are risk factors for scleroderma renal crisis.

Authors:  Binh Nguyen; Maureen D Mayes; Frank C Arnett; Deborah del Junco; John D Reveille; Emilio B Gonzalez; Hilda T Draeger; Marilyn Perry; Amir Hendiani; Kiran K Anand; Shervin Assassi
Journal:  Arthritis Rheum       Date:  2011-02

4.  Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis.

Authors:  Minoru Hasegawa; Manabu Fujimoto; Takashi Matsushita; Yasuhito Hamaguchi; Kazuhiko Takehara; Shinichi Sato
Journal:  Clin Rheumatol       Date:  2010-11-04       Impact factor: 2.980

5.  Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma.

Authors:  Robyn T Domsic; Tatiana Rodriguez-Reyna; Mary Lucas; Noreen Fertig; Thomas A Medsger
Journal:  Ann Rheum Dis       Date:  2010-08-02       Impact factor: 19.103

Review 6.  [Renal manifestations of rheumatic diseases].

Authors:  A Schwarting; E Märker-Hermann
Journal:  Z Rheumatol       Date:  2005-02       Impact factor: 1.372

Review 7.  Scleroderma renal crisis: a rare but severe complication of systemic sclerosis.

Authors:  Luc Mouthon; Alice Bérezné; Guillaume Bussone; Laure-Hélène Noël; Peter M Villiger; Loïc Guillevin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

8.  What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG).

Authors:  Xiangning Fan; Janet Pope; Murray Baron
Journal:  Rheumatol Int       Date:  2009-09-24       Impact factor: 2.631

9.  An International, Web-Based, Prospective Cohort Study to Determine Whether the Use of ACE Inhibitors prior to the Onset of Scleroderma Renal Crisis Is Associated with Worse Outcomes-Methodology and Preliminary Results.

Authors:  Marie Hudson; Murray Baron; Ernest Lo; Joanna Weinfeld; Daniel E Furst; Dinesh Khanna
Journal:  Int J Rheumatol       Date:  2010-09-14

Review 10.  Determinants of mortality in systemic sclerosis: a focused review.

Authors:  Dilli Ram Poudel; Divya Jayakumar; Abhijeet Danve; Shiv Tej Sehra; Chris T Derk
Journal:  Rheumatol Int       Date:  2017-11-07       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.